Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ADXS31-142 |
Synonyms | |
Therapy Description |
ADXS31-142 consists of a live attenuated Listeria monocytogenes encoding prostate-specific antigen (PSA) and listeriolysin O (LLO) fusion protein which may have immunostimulatory and antitumor activities (PMID: 22644735). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADXS31-142 | ADXS-PSA | ADXS31-142 consists of a live attenuated Listeria monocytogenes encoding prostate-specific antigen (PSA) and listeriolysin O (LLO) fusion protein which may have immunostimulatory and antitumor activities (PMID: 22644735). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02325557 | Phase Ib/II | Pembrolizumab ADXS31-142 | ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046 | Completed | USA | 0 |